GSK drops Phase 3 chronic cough drug in a blow to $2B Bellus Health buyout

July 17, 2026 07:05 AM EDT R&DPharma GSK drops Phase 3 chron­ic cough drug in a blow to $2B Bel­lus Health buy­out Ayisha Sharma News Reporter In a ma­jor stum­ble for GSK’s $2 bil­lion ac­qui­si­tion of Bel­lus Health, the UK phar­ma said Fri­day it is end­ing de­vel­op­ment … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER